Corrigendum to "Structure-activity study for (bis)ureidopropyl- and (bis)thioureidopropyldiamine LSD1 inhibitors with 3-5-3 and 3-6-3 carbon backbone architectures" [Bioorg. Med. Chem. 23 (2015) 1601-1612]
Bioorg Med Chem. 2018 Jul 23;26(12):3728-3729.
doi: 10.1016/j.bmc.2018.05.032.
Epub 2018 May 30.
1 Sidney Kimmel Comprehensive Cancer Center, John Hopkins University, Baltimore, MD 21231, United States.
2 Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, 70 President St., Charleston, SC 29425, United States.
3 Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy, Wayne State University, 259 Mack Avenue, Detroit, MI 48202, United States.
4 Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, 70 President St., Charleston, SC 29425, United States. Electronic address: woster@musc.edu.